第4章：非癌性人乳头瘤病毒相关疾病的负担与管理：人乳头瘤病毒6/11型疾病

Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease.

作者信息

Lacey Charles J N, Lowndes Catherine M, Shah Keerti V

机构信息

Hull York Medical School, University of York, Heslington, York, UK.

出版信息

Vaccine. 2006 Aug 31;24 Suppl 3:S3/35-41. doi: 10.1016/j.vaccine.2006.06.015.

DOI:10.1016/j.vaccine.2006.06.015

PMID:16950016

Abstract

Human Papillomavirus (HPV)-6 and -11 are the causative agents of ano-genital warts (GWs) and recurrent respiratory papillomatosis (RRP). They are low-risk HPV types that are uncommonly found in malignant lesions. GWs are an extremely prevalent sexually transmitted disease, whereas RRP is a rare disease that can be life threatening and requires multiple surgical procedures. GWs and RRP cause substantial healthcare costs. A quadrivalent HPV-6/11/16/18 vaccine (Merck/SPMSD) has shown essentially 100% protection against GWs in women in early studies. Cost-effectiveness analyses are needed to assess the benefits of the HPV-6/11 virus-like particle (VLP) components of the quadrivalent vaccine in population-based vaccination programmes.

摘要

人乳头瘤病毒（HPV）-6型和-11型是引起肛门生殖器疣（GWs）和复发性呼吸道乳头瘤病（RRP）的病原体。它们是低风险的HPV类型，在恶性病变中很少见。GWs是一种极其常见的性传播疾病，而RRP是一种罕见疾病，可能危及生命，需要多次手术。GWs和RRP会导致大量医疗费用。一种四价HPV-6/11/16/18疫苗（默克/SPMSD）在早期研究中已显示对女性GWs的保护率基本达到100%。需要进行成本效益分析，以评估四价疫苗中HPV-6/11病毒样颗粒（VLP）成分在基于人群的疫苗接种计划中的益处。